Evidence map›Paper›PMID 41663693›Full record

ArticleDiscover oncology2026

Hepatic stellate cell derived lipid droplets drive protumoral M2 macrophage polarization in hepatocellular carcinoma.

Yundan You, Sha Huang, Jingjie Xu, Qifei Li, Yu Wang, Zhouwei Zhan, Yong Ye, Bin Lan, Xuefeng Wang, Zengqing Guo and 1 more

Abstract read
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yundan You *Depatment of intensive care unit, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Sha Huang *Depatment of medical oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Jingjie XuDepatment of medical oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Qifei LiDepatment of medical oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Yu WangDepartment of hepatobiliary surgery, Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China.
Zhouwei ZhanDepatment of medical oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Yong YeDepatment of intensive care unit, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Bin LanDepatment of medical oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Xuefeng WangDepatment of medical oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Zengqing GuoDepatment of medical oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China. gzq_005@126.com.
Qiaoting HuDepatment of medical oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China. hqt_trc@fjmu.edu.cn.

Funding

Fujian Provincial Health Technology Project 2022ZD01005Fujian Provincial Health Technology Project 2024GGA046High-level Talent Project (Category C) of Fujian Cancer Hospital 2024YNG02Innovation of Science and Technology, Fujian province 2021Y9218Innovation of Science and Technology, Fujian province 2023Y9447Innovation of Science and Technology, Fujian province 2023Y9448Innovation of Science and Technology, Fujian province 2024Y9603Innovation of Science and Technology, Fujian province 2024Y9613Natural Science Foundation of Fujian Province 2023J05236Natural Science Foundation of Fujian Province 2023J05239Natural Science Foundation of Fujian Province 2023J06038Natural Science Foundation of Fujian Province 2024J011064Sciences Foundation of Fujian Cancer Hospital 2023YN05Startup Fund for scientific research, Fujian Medical University 2022QH1147
6 · The paper itself

Abstract

backgroundDuring chronic liver injury, hepatic stellate cells (HSCs) lose their vitamin-A-rich lipid droplets (LDs), yet whether these organelles are merely degraded or released via vesicles and functionally relevant remains unclear. We investigated the fate of HSCs LDs and their impact on hepatic macrophage phenotype and hepatocellular carcinoma (HCC) development.

methodsChronic liver injury was induced in C57BL/6 mice using carbon tetrachloride (CCl

resultsActivated HSCs in fibrotic livers showed progressive fragmentation and release of LDs, which were subsequently internalized by hepatic macrophages. Single-cell transcriptomic analysis revealed enhanced HSC-macrophage interactions and upregulation of lipid metabolism pathways in both cell types during liver inflammation. HSC-derived LDs acted as a direct metabolic cue to induced M2 polarization of macrophages, characterized by elevated secretion of transforming growth factor-beta (TGF-β1), interleukin-10 (IL-10), and C-C Motif Chemokine Ligand 17 (CCL17). In orthotopic HCC models, co-injection of tumor cells with lipid droplet-educated macrophages significantly enhanced tumor growth compared to control macrophages. TCGA analysis showed that high CD163 expression correlated with poor overall survival in HCC patients.

conclusionOur findings identifies a distinct mechanism whereby activated HSCs transfer LDs to hepatic macrophages, inducing M2 polarization and creating a pro-tumorigenic microenvironment. This HSC-macrophage crosstalk represents a potential metabolic therapeutic target for preventing HCC development in patients with chronic liver disease.

Indexed as

Hepatic stellate cellHepatocellular carcinomaLipid dropletMetabolic reprogramming.Tumor-Associated macrophageTumor microenvironment

Identifiers

PMID41663693
PMCPMC12996580

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.